Agrow is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New ai applications progress in EU

The European Commission has recognised applications for three new active ingredients as complete. DuPont submitted an application for its sulfonylurea herbicide, ethametsulfuron, to the UK, as rapporteur member state, last June. Ethametsulfuron is well-established outside the EU, having been introduced in Canada in 1991 and the US in 2001 for use in canola. Syngenta applied to France last June for its fungicide, sedaxane. It is also seeking US approval on maize, soybeans, cereals and canola, and expects to launch the ai in 2012 ( Agrow No 600, p 14). Bayer CropScience applied to France last September for the bionematicide, Bacillus firmus I-1582. It acquired the product from Israeli biopesticide company AgroGreen in 2009 ( Agrow No 565, p 2). B firmus is registered in Israel as BioNem for use on vegetables and other crops. Completeness is an early stage in the EU registration process and gives rapporteurs up to a year to carry out detailed evaluations.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG004405

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel